Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

This is a multicenter, randomized, open-label, Phase 3 study

Participants needed: 165
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Shanghai Kechow Pharma, Inc.Updated: Sep 18, 2025Locations: 1
Eligibility criteria

Before study entry, written informed consent must be obtained from the patient p... [+10]

Prior treatment with any BRAF and MEK inhibitor; [+12]

Read more
Status: Recruiting

Safety, Tolerability, and Pharmacokinetics of HL-003 in Healthy Subjects

This clinical study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of HL-003 tablets in healthy subjects. It is conducted in two sequential clinical phases: single-dose and multiple-dose escalation.

Participants needed: 52
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: Shanghai Kechow Pharma, Inc.Updated: Mar 10, 2025Locations: 1
Eligibility criteria

Volunteers must be between 18 and 50 years old (inclusive), healthy, and can be... [+5]

History of known allergy to the investigational drug or any of its components/re... [+19]

Read more
Status: Recruiting

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who have received immunotherapy before. Subjects were stratified according to the baseline lactate dehydrogenase level and chemotherapy.

Participants needed: 165
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Kechow Pharma, Inc.Updated: Jun 28, 2024Locations: 1
Eligibility criteria

≥ 18 years of age. [+10]

Having the following treatment before receiving the study drug: ① received chemo... [+19]

Read more
Status: Recruiting

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)

Participants needed: 70
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Kechow Pharma, Inc.Updated: May 31, 2023Locations: 1
Eligibility criteria

Age: patients must be ≥18 years of age at the time of study entry. [+4]

Patients who are unable to undergo MRI scans (prosthesis, prosthesis, braces, et... [+11]

Read more